BNTX Company Profile and Key Details
BioNTech SE
BNTX Stock Price Chart
Stock Price Today
BioNTech SE (BNTX) stock surged +4.75%, trading at $117.25 on NASDAQ, up from the previous close of $111.93. The stock opened at $112.35, fluctuating between $111.13 and $118.39 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Company Information
| Employees | 6133 |
| Beta | 0.26 |
| Sales or Revenue | $3.82B |
| 5Y Sales Change% | 26.959% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
BioNTech SE (NASDAQ: BNTX) stock price is $117.25 in the last trading session. During the trading session, BNTX stock reached the peak price of $118.39 while $111.13 was the lowest point it dropped to. The percentage change in BNTX stock occurred in the recent session was 4.75% while the dollar amount for the price change in BNTX stock was $5.32.
The NASDAQ listed BNTX is part of Biotechnology industry that operates in the broader Healthcare sector. BioNTech SE designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Prof. Ugur Sahin M.D.
Co-Founder, Chief Executive Officer & Chair of the Management Board
Dr. Ozlem Tureci M.D.
Co-Founder, Chief Medical Officer & Member of Management Board
Mr. Jens H. Holstein
Chief Financial Officer & Member of Management Board
Dr. Sierk Poetting Ph.D.
MD, Chief Operating Officer & Member of Management Board
Mr. Ryan Richardson
Chief Strategy Officer, MD & Member of Management Board
Mr. Sean Marett
Chief Bus. Officer, Chief Commercial Officer & Member of Management Board
Prof. Christoph Hubert Huber M.D., Ph.D.
Co-Founder & Member of Supervisory Board
Michael Boehler
MD & Head of Global External Communications
Dr. Oliver Hennig Ph.D.
Senior Vice President of Operations
Sylke Maas Ph.D.
Vice President of Investor Relations and Bus. Strategy
Dr. James Timothy Patrick Ryan Ph.D.
Senior Vice President of Legal & IP and Gen. Counsel
BNTX's closing price is 46.26% higher than its 52-week low of $76.53 where as its distance from 52-week high of $131.49 is -14.88%.
Number of BNTX employees currently stands at 6,133.
Official Website of BNTX is: https://www.biontech.de
BNTX could be contacted at phone 496 131 90840 and can also be accessed through its website. BNTX operates from An der Goldgrube 12, Mainz, 55131, Germany.
BNTX stock volume for the day was 660.24K shares. The average number of BNTX shares traded daily for last 3 months was 827.45K.
The market value of BNTX currently stands at $28.11B with its latest stock price at $117.25 and 239.74M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com